Abstract:Background: C-X-C chemokine receptor type 4 (CXCR4) has been implicated in the invasiveness and metastasis of diverse cancers. However, the published data remain controversial on the correlation between CXCR4 expression level, as well as its subcellular distribution in tumor cells, and the clinical outcome of patients with breast cancer. Methods: To identify the precise role of CXCR4 in the clinical outcome of breast cancer, we performed a meta-analysis including 15 published studies. Original data included the hazard ratios (HRs) of overall survival (OS) and disease-free survival (DFS) in breast cancer with high CXCR4 expression versus low expression. We pooled hazard ratios (HRs) with 95% confidence intervals (CIs) to estimate the hazard. Results: A total of 15 published studies (including 3104 patients) were eligible. Overall survival (OS) and disease-free survival (DFS) of breast cancer were found to be significantly related to CXCR4 expression level, with the HR being 1.65 (95% CI: 1.34-2.03; P < 0.00001) and 1.94 (95% CI: 1.42-2.65; P < 0.00001) respectively. Stratified analysis according to subcellular distribution of CXCR4 showed that high expression in whole cells, cytoplasm and nucleus could predict unfavorable OS, with the HR of 2.02 (95% CI: 1.43-2.85; P < 0.0001), 1.57 (95% CI: 1.13-2.18; P = 0.007), and 1.47 (95% CI: 1.19-1.81; P = 0.0004) respectively. As for DFS, elevated expression level of CXCR4 both in whole cells and cytoplasm predicted a poor outcome, with the HR being 2.23 (95% CI: 1.48-3.37; P = 0.0001) and 1.76 (95% CI: 1.11-2.80; P = 0.02), while high expression in the nucleus had no statistical significance, with HR 1.15 (95% CI: 0.52-2.55; P = 0.73). Conclusions: Increased CXCR4 expression, especially in whole cells and cytoplasm, may serve as a poor prognostic indicator in patients with breast cancer. Future studies are warranted to investigate the relationship between CXCR4 expression and survival of patients with breast carcinoma, which could help predict the clinical outcome and guide clinical decision-making for therapy. (C) 2013 Elsevier Ltd. All rights reserved.

Expression and Clinical Significance of the CXC Chemokine Receptor-4 (CXCR4) in Breast Cancer

Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node metastasis in human breast cancer.

The expression of chemokine receptor CXCR4 in colorectal cancer and its clinical significance

Expression Analysis of CXCR4 in Primary Breast Carcinoma Tissues by SYBR Green Quantitative Real-Time PCR

Cytoplasmic CXCR4 High-Expression Exhibits Distinct Poor Clinicopathological Characteristics and Predicts Poor Prognosis in Triple-Negative Breast Cancer

Expression of CXCR4 in Lung Cancer and Its Significance

The Impact of Chemokine Receptor CXCR4 on Breast Cancer Prognosis: A Meta-Analysis

The chemokine receptor CCR4 promotes tumor growth and lung metastasis in breast cancer

CXCR4 Expression in Bladder Transitional Cell Carcinoma and Its Relationship with Clinicopathological Features

Role of CXCR4 expression in progress and prognosis of breast cancer

Expression and clinical significance of CXCR4 in clear cell renal cell cancer

Expression of CXCR4 and Breast Cancer Prognosis: a Systematic Review and Meta-Analysis

Expression of CXCR4 in Breast Cancer and the Relationship Between CXCR4 and Hedgehog Signaling Pathway

Expression of Cxcl14 and Its Anticancer Role in Breast Cancer

Expression of Chemokine Receptor CXCR4 in Lewis Lung Carcinoma Cells

CXCL12/CXCR4 and breast cancer

Role of CXCR4 in Lymph Node Metastasis Promoted by VEGF-C in Gastric Carcinoma

The role of CXC chemokine ligand 4/CXC chemokine receptor 3-B in breast cancer progression

Expression and Significance of Chemokine Receptor CXCR4 in Clear Cell Renal Cell Cancer

Comprehensive analysis of the prognostic value and immune function of chemokine-CXC receptor family members in breast cancer.

Research progress about CXCR4 and tumor